Clinical Trial Update: Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating tolerance and safety of a subconjunctival dexamethasone-releasing implant for immunosuppression during penetrating keratoplasty.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hereditary Stromal Dystrophy of the Cornea
• Fuchs Endothelial Dystrophy
• Keratoconus

Drugs mentioned

• dexamethasone-releasing subconjunctival implant (dexamethasone)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Keratoconus, Fuchs' Endothelial Dystrophy | Phase 2 | Status: COMPLETED